| Literature DB >> 29033915 |
Alexis Naf1,2, Marie Decalonne2, Sandra Dos Santos1,3, Laurent Mereghetti3, Nathalie L van der Mee-Marquet1,2,3.
Abstract
We compared the performance of incontinence product (IP) and rectal swabbing for the detection of multidrug-resistant Enterobacteriaceae (MDRE) carriage in a large multicenter study conducted in February 2017 among the residents of 23 French nursing homes. The study included 547 residents who habitually wore IP, 88 of whom were MDRE carriers (16.1%). Positive results were obtained for both rectal and IP swabs for 64 of these residents, for rectal swabs only for 22 and for IP swabs only for two of these patients. The estimated prevalence of MDRE carriage depended on the type of sample: 15.7% for rectal swabs and 12.1% for IP swabs (p < 0.001). The positive percent agreement was 84.2% and the negative percent agreement was 97.4%. Rectal swabbing remains the best method for detecting MDRE carriage in elderly residents, but our findings provide support for the use of swabs from IP used overnight to increase response rates in MDRE surveys in elderly residents that habitually wear IP, when rectal swabbing is not feasible.Entities:
Keywords: ESBL-producing enterobacteriaceae; asymptomatic carriage; carbapenemase-producing enterobacteriaceae; infection control; multi-resistant bacteria; nursing homes; rectal swabbing
Year: 2017 PMID: 29033915 PMCID: PMC5627303 DOI: 10.3389/fmicb.2017.01858
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Demographic and clinical characteristics of residents testing positive (n = 99) and negative (n = 581) for ESBLE carriage in the 23 NHs.
| Age > 87 years | 44 (44.4) | 308 (53.0) | |
| Physical disability | 73 (73.7) | 411 (70.7) | |
| Comorbid conditions | |||
| Diabetes mellitus | 15 (15.1) | 100 (17.2) | |
| Cancer | 2 (2.0) | 36 (6.2) | |
| McCabe 1 or 2 | 58 (58.6) | 357 (61.4) | |
| Incontinence | |||
| Urinary | 87 (87.9) | 461 (79.3) | 0.047 |
| Fecal | 73 (73.7) | 389 (66.9) | |
| Hospitalization in the last 6 months | 24 (24.2) | 110 (18.9) | |
| Antibiotic use in the last 6 months | 46 (46.5) | 188 (32.3) | 0.006 |
| Clavulanate-amoxicillin | 6 (6.1) | 30 (5.2) | |
| Fluoroquinolones | 6 (6.1) | 23 (3.9) | |
| 3rd-generation cephalosporins | 16 (16.2) | 46 (7.9) | 0.008 |
| Vancomycin | 0 | 1 (<0.1) | |
| Carbapenems | 2 (2.0) | 0 | 0.015 |
| Infection on the day of the study | 2 (2.0) | 18 (3.1) |
Antibiotic susceptibility pattern of the 99 ESBLSE isolates.
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | NET | GM | NA | OFX | CIP | SXT | 2 | |||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | AN | TM | NET | NA | OFX | CIP | SXT | 1 | |||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | NA | OFX | CIP | SXT | 1 | |||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | NA | OFX | CIP | SXT | 1 | ||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | ERM | NA | OFX | CIP | SXT | 2 | |||||
| AMOX | TICAR | PIP | CN | CTX | ATM | FEP | TM | NA | OFX | CIP | SXT | 1 | ||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | TM | NA | OFX | CIP | SXT | 1 | |||||||
| AMOX | TICAR | PIP | CN | CTX | TM | NA | OFX | CIP | SXT | 2 | ||||||||
| AMOX | TICAR | PIP | CN | CTX | NA | OFX | CIP | SXT | 2 | |||||||||
| AMOX | TICAR | PIP | CN | CTX | CAZ | NA | OFX | CIP | SXT | 1 | ||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | AN | TM | NET | GM | NA | OFX | CIP | 1 | |||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | NET | GM | NA | OFX | CIP | 2 | ||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | GM | NA | OFX | CIP | 1 | |||||
| AMOX | TICAR | PIP | CN | CTX | FEP | TM | GM | NA | OFX | CIP | 1 | |||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | TM | NA | OFX | CIP | 1 | |||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | NA | OFX | CIP | 1 | |||||||
| AMOX | TICAR | PIP | CN | CTX | FEP | NA | OFX | CIP | 2 | |||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | NA | OFX | CIP | 10 | |||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | ERM | NA | OFX | CIP | 1 | ||||||
| AMOX | TICAR | PIP | CN | CTX | NA | OFX | CIP | 4 | ||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | NA | 1 | ||||||||||
| AMOX | TICAR | PIP | CN | CTX | NA | SXT | 2 | |||||||||||
| AMOX | TICAR | PIP | CN | CTX | FEP | NA | SXT | 1 | ||||||||||
| AMOX | TICAR | PIP | CN | CTX | CAZ | NA | 1 | |||||||||||
| AMOX | TICAR | PIP | CN | CTX | NA | 1 | ||||||||||||
| AMOX | TICAR | PIP | CN | CTX | SXT | 2 | ||||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | SXT | 1 | ||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | SXT | 1 | |||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | 6 | ||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | 1 | |||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | 1 | ||||||||||||
| AMOX | TICAR | PIP | CN | CTX | 5 | |||||||||||||
| AMOX | TICAR | PIP | CN | CTX | FEP | TM | NET | 1 | ||||||||||
| AMOX | TICAR | PIP | CTX | FEP | SXT | 1 | ||||||||||||
| AMOX | TICAR | PIP | CTX | CAZ | 1 | |||||||||||||
| AMOX | TICAR | PIP | CTX | 1 | ||||||||||||||
| AMOX | TICAR | PIP | CN | CTX | 1 | |||||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | ERM | AN | TM | NET | GM | NA | OFX | CIP | SXT | 1 | |
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | NET | GM | NA | OFX | CIP | SXT | 4 | |||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | TM | GM | NA | OFX | CIP | SXT | 1 | |||||
| AMOX | TICAR | PIP | CN | CTX | ATM | FEP | ERM | NA | OFX | SXT | 1 | |||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | NA | OFX | CIP | SXT | 1 | |||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | OFX | CIP | SXT | 5 | ||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | TM | OFX | CIP | SXT | 1 | |||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | CIP | SXT | 3 | |||||||
| AMOX | TICAR | PIP | CN | CTX | CAZ | FEP | TM | CIP | SXT | 2 | ||||||||
| AMOX | TICAR | PIP | CN | CTX | FEP | SXT | 2 | |||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | FEP | SXT | 1 | ||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | TM | NET | NA | OFX | CIP | 1 | ||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | NA | OFX | CIP | 4 | |||||||
| AMOX | TICAR | PIP | CN | CTX | 1 | |||||||||||||
| AMOX | TICAR | CN | CTX | ATM | CAZ | NA | OFX | CIP | 1 | |||||||||
| AMOX | TICAR | PIP | CN | CTX | 1 | |||||||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | ERM | AN | TM | NET | GM | NA | OFX | CIP | SXT | 1 | |
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | GM | 1 | ||||||||
| AMOX | TICAR | PIP | CN | CTX | ATM | CAZ | FEP | TM | NET | GM | NA | OFX | CIP | SXT | 1 | |||
AMOX, amoxicillin; TICAR, ticarcillin; PIP, piperacillin; CN, CTX cefotaxime; ATM, aztreonam; CAZ, ceftazidime; FEP, cefpirome; ERM, ertapenem; AN, amikacin; TM, tobramycin; NET, netilmicin; GM, gentamicin; NA, nalidixic acid; OFX, ofloxacin; CIP, ciprofloxacin; SXT, trimethoprim-sulfamethoxazole.
Figure 1Distribution of positive and negative rectal and IP swabs.
Comparison of the ESBLE carriage detection rates obtained with rectal (R) and incontinence product (IP) swabs.
| nh3280 | 25 | 25 | 0 | 0 | |||
| nh143 | 29 | 28 | 1 | 3.4 | 0 | ||
| nh3378 | 25 | 24 | 1 | 4.0 | 0 | ||
| nh3247 | 23 | 22 | 1 | 4.3 | 4.3 | ||
| nh3245 | 21 | 20 | 1 | 4.8 | 4.8 | ||
| nh3272 | 19 | 18 | 1 | 5.3 | 5.3 | ||
| nh3335 | 27 | 25 | 1 | 1 | 7.4 | 3.7 | |
| nh3175 | 26 | 24 | 1 | 1 | 7.7 | 3.8 | |
| nh136 | 23 | 21 | 2 | 8.7 | 8.7 | ||
| nh3316 | 18 | 16 | 2 | 9.7 | 0 | ||
| nh3297 | 20 | 18 | 2 | 10.0 | 10.0 | ||
| nh3066 | 17 | 15 | 2 | 11.8 | 11.8 | ||
| nh3127 | 27 | 23 | 2 | 2 | 14.8 | 7.4 | |
| nh3073 | 26 | 22 | 3 | 1 | 15.4 | 11.5 | |
| nh3315 | 25 | 20 | 3 | 1 | 1 | 16.0 | 16.0 |
| nh3369 | 25 | 21 | 3 | 1 | 16.0 | 12.0 | |
| nh3340 | 30 | 25 | 4 | 1 | 16.7 | 13.3 | |
| nh3167 | 25 | 20 | 4 | 1 | 20.0 | 16.0 | |
| nh3114 | 22 | 17 | 4 | 1 | 22.7 | 18.2 | |
| nh3097 | 16 | 12 | 2 | 2 | 25.0 | 12.5 | |
| nh3327 | 26 | 19 | 4 | 3 | 26.9 | 15.4 | |
| nh3162 | 28 | 14 | 11 | 2 | 1 | 46.4 | 42.9 |
| nh3111 | 24 | 10 | 13 | 1 | 58.3 | 54.2 | |
| All | 596 | 459 | 64 | 22 | 2 | 15.7 | 11.1 |